An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors.

Trial Profile

An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2017

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Carcinoid tumour; Neuroendocrine tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Apr 2017 Planned End Date changed from 1 Dec 2018 to 1 Apr 2022.
    • 14 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2018.
    • 21 Jan 2017 Results (n=61) assessing the efficacy and safety of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors, presented at the 2017 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top